SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+16.87%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$493M
AUM Growth
+$4.13M
(+0.85%)
Cap. Flow
-$9.41M
Cap. Flow
% of AUM
-1.91%
Top 10 Holdings %
Top 10 Hldgs %
38.08%
Holding
111
New
22
Increased
19
Reduced
35
Closed
22
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$13.5M |
| 2 |
Cigna
CI
|
+$9.96M |
| 3 |
Merck
MRK
|
+$9.66M |
| 4 |
Icon
ICLR
|
+$9.38M |
| 5 |
GSK
GSK
|
+$9.35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$13.1M |
| 2 |
Cencora
COR
|
+$12.5M |
| 3 |
Walgreens Boots Alliance
WBA
|
+$12.3M |
| 4 |
Sanofi
SNY
|
+$10.7M |
| 5 |
Amgen
AMGN
|
+$9.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.92% |
| 2 | Miscellaneous | 7.07% |
| 3 | Consumer Staples | 1.34% |
| 4 | Technology | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Curis
CRIS
$1.45M
| $49.6M | 10.07% |
10,954
-937
| -8% | -$3.92M |
2020 Q2
3 quarters
|
|
|
2
Cigna
CI
$76.5B
| $25.9M | 5.25% |
106,965
+44,700
| +72% | +$9.96M |
2020 Q3
2 quarters
|
|
3
Cardinal Health
CAH
$57.4B
| $16.7M | 3.39% |
274,917
+119,700
| +77% | +$6.61M |
2020 Q2
3 quarters
|
|
4
SPDR Gold Trust
GLD
$139B
| $15.5M | 3.15% |
97,009
-5,500
| -5% | -$924K |
2020 Q1
4 quarters
|
|
|
SOLY
5
DELISTED
Soliton, Inc.
SOLY
| $14.5M | 2.94% |
824,803
-37,602
| -4% | -$481K |
2020 Q2
3 quarters
|
|
|
6
Centene
CNC
$34.7B
| $13.9M | 2.82% |
+217,500
| New | +$13.5M |
2021 Q1
0 quarters
|
|
7
HCA Healthcare
HCA
$102B
| $13.8M | 2.8% |
73,173
-7,572
| -9% | -$1.34M |
2018 Q1
12 quarters
|
|
8
Spruce Biosciences
SPRB
$112M
| $13.5M | 2.74% |
10,838
+2,349
| +28% | +$3.61M |
2020 Q4
1 quarter
|
|
9
Coherus Oncology
CHRS
$162M
| $12.4M | 2.51% |
847,862
-16,194
| -2% | -$275K |
2019 Q2
7 quarters
|
|
|
HRC
10
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $11.9M | 2.41% |
107,647
-15,551
| -13% | -$1.62M |
2020 Q2
3 quarters
|
|
11
PUT
CEL-SCI Corp
CVM
$30.1M
| $10.6M | 2.15% |
23,190
-47,497
| -67% | -$25.9M |
2019 Q3
6 quarters
|
|
|
12
Merck
MRK
$364B
| $9.64M | 1.96% |
+131,000
| New | +$9.66M |
2021 Q1
0 quarters
|
|
|
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
| $9.46M | 1.92% |
268,346
-85,864
| -24% | -$3.17M |
2020 Q3
2 quarters
|
|
14
United Therapeutics
UTHR
$23.2B
| $9.37M | 1.9% |
56,044
+17,310
| +45% | +$2.89M |
2018 Q4
9 quarters
|
|
|
15
Icon
ICLR
$13B
| $9.33M | 1.89% |
+47,500
| New | +$9.38M |
2021 Q1
0 quarters
|
|
|
16
GSK
GSK
$95.9B
| $9.19M | 1.87% |
+206,000
| New | +$9.35M |
2021 Q1
0 quarters
|
|
17
AMN Healthcare
AMN
$1.46B
| $9.13M | 1.85% |
123,898
-6,700
| -5% | -$498K |
2020 Q3
2 quarters
|
|
18
Universal Health Services
UHS
$11B
| $9.09M | 1.84% |
68,135
-12,708
| -16% | -$1.69M |
2020 Q4
1 quarter
|
|
19
DELISTED
ESSA Pharma
EPIX
| $9.08M | 1.84% |
312,711
-120,312
| -28% | -$2.8M |
2020 Q3
2 quarters
|
|
20
Mirum Pharmaceuticals
MIRM
$5.19B
| $8.66M | 1.76% |
437,138
-57,605
| -12% | -$1.1M |
2020 Q4
1 quarter
|
|
21
BioLineRX
BLRX
$10.4M
| $7.65M | 1.55% |
+68,544
| New | +$8.24M |
2021 Q1
0 quarters
|
|
22
McKesson
MCK
$114B
| $7.59M | 1.54% |
38,893
-8,569
| -18% | -$1.56M |
2019 Q3
6 quarters
|
|
23
X4 Pharmaceuticals
XFOR
$243M
| $6.93M | 1.41% |
+26,820
| New | +$7.05M |
2021 Q1
0 quarters
|
|
24
Herbalife
HLF
$1.49B
| $6.6M | 1.34% |
148,719
+71,059
| +92% | +$3.5M |
2020 Q3
2 quarters
|
|
|
RCOR
25
DELISTED
Renovacor, Inc.
RCOR
| $6.41M | 1.3% |
+600,000
| New | +$6.21M |
2021 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Sio Capital Management held 111 positions worth $493M, up 0.85% from $489M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Sio Capital Management's Q1 2021 filing shows 22 new, 19 increased, 35 reduced and 22 closed positions. Its largest new stake was Centene: 217,500 shares worth $13.9M. The largest sale was AstraZeneca, an estimated $13.1M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Sio Capital Management's largest Q1 2021 buy was Centene: 217,500 shares worth $13.9M.
- Sio Capital Management added most to Cigna in Q1 2021, an estimated $9.96M increase.
- Sio Capital Management's biggest Q1 2021 reduction was Curis, cutting an estimated $3.92M.
- Sio Capital Management fully exited AstraZeneca in Q1 2021, selling an estimated $13.1M.
- Sio Capital Management's ten largest holdings make up 38% of its $493M portfolio in Q1 2021.
- Sio Capital Management opened 22 new positions and closed 22 in Q1 2021.
- Sio Capital Management's portfolio value rose 0.85% quarter-over-quarter to $493M.
Based on Sio Capital Management's 13F filing for Q1 2021, filed 14 May 2021.